4-氟-2-甲基苯甲酸乙酯 | 167758-88-5

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟苯甲酸系列
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2-甲基苯甲酸乙酯
• 中文别名: 2-甲基-4-氟苯甲酸乙酯
• 英文名称: ethyl 4-fluoro-2-methylbenzoate
• CAS: 167758-88-5
• 化学式: C₁₀H₁₁FO₂
• mdl: MFCD06204529
• 分子量: 182.195
• InChiKey: RLCFHMSCTWXLTQ-UHFFFAOYSA-N

物化性质

• 沸点：
  226.2±20.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P330,P362,P403+P233,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  4-氟-2-甲基苯甲酸乙酯 在 一水合肼 作用下， 以 二甲基亚砜 为溶剂， 反应 4.0h， 以86%的产率得到ethyl 4-hydrazino-2-methylbenzoate
  参考文献：
  名称：

  Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists

  摘要：

  G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders. During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzy1)-5-methyl-1H-1,2,4-triazol-1-y1)-2-methylbenzamide (4u; half maximal effective concentration (EC50) = 75 nM, maximal response (E-max) = 122%) starting from a high-throughput screening hit 3 (EC50 = 470 nM, E-max = 56%). The structural features of a reported GPR52 agonist were applied to 3, led to design 4-azolylbenzamides as novel GPR52 agonists. A structure-activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole derivative 4u, which demonstrated excellent bioavailability in rats (F = 53.8%). Oral administration of 4u (10 mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice. Thus, 4u is a promising lead compound for drug discovery research of GPR52 agonists. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.03.064
• 作为产物：
  描述：

  4-氟-2-甲基苯甲酸 、 碘乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.75h， 以85.8%的产率得到4-氟-2-甲基苯甲酸乙酯
  参考文献：
  名称：

  一种哒嗪酮衍生物及其用途

  摘要：

  本发明属于药物领域，具体涉及一种哒嗪酮衍生物及其用途，其化合物及其药学上可接受的盐、溶剂化物包括水合物、多晶体、前药、共晶体、互变异构物、立体异构体，更具体地说，本发明所述的化合物可以作为具有CEN抑制作用的抗流感药物。

  公开号：

  CN114057730A

文献信息

• 流感病毒复制抑制剂及其用途
  申请人：广东东阳光药业有限公司

  公开号：CN111057074B

  公开（公告）日：2022-04-29

  本发明属于药物领域，具体涉及一类作为流感病毒复制抑制剂的新化合物及其制备方法、包含所述化合物的药物组合物以及所述化合物及其药物组合物在治疗流感中的应用。本发明的化合物，其为式(I)所示化合物或式(I)所示化合物的立体异构体、互变异构体、氮氧化物、溶剂化物、代谢产物、药学上可接受的盐或它们的前药，本发明的化合物能很好的抑制流感病毒，和/或具有更低的细胞毒性，更优良的体内代谢动力学性质和体内药效学性质。
• Novel cyclic amide derivatives
  申请人：——

  公开号：US20030212094A1

  公开（公告）日：2003-11-13

  Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient: 1 wherein X represents an alkyl group, an aryl group, a heterocyclic group or the like; Q represents a group represented by —CH 2 —, —CO—, —O—, —CH(OR 7 )— or the like wherein R 7 represents a hydrogen atom, an alkyl group or the like; n represents an integer of from 0 to 5; R 1 and R 2 each represent a hydrogen atom, an alkyl group or the like; B represents either of the following groups: 2 wherein R 3 , R 4 , R 5 , and R 6 each represent a hydrogen atom, a halogen atom, an alkoxyl group or the like; m represents 1 or 2; and the ring of: 3 represents an aromatic heterocyclic ring.

  以下公式（I）表示的新化合物作为sigma受体/结合位点的配体，并包括作为活性成分的药物： 其中X代表烷基、芳基、杂环基或类似基团；Q代表由—CH 2 —、—CO—、—O—、—CH(OR 7 )—或类似基团表示的基团，其中R 7 代表氢原子、烷基或类似基团；n代表从0到5的整数；R 1 和R 2 各自代表氢原子、烷基或类似基团；B代表以下任一基团： 其中R 3 、R 4 、R 5 和R 6 各自代表氢原子、卤素原子、烷氧基或类似基团；m代表1或2；以及： 代表芳香杂环环。
• [EN] INFLUENZA VIRUS REPLICATION INHIBITOR AND USES THEREOF<br/>[FR] INHIBITEUR DE LA RÉPLICATION DU VIRUS DE LA GRIPPE ET UTILISATIONS ASSOCIÉES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2020078401A1

  公开（公告）日：2020-04-23

  The invention belongs to the field of medicine, and particularly relates to a novel compound as a replication inhibitor of influenza virus and a preparation method thereof, a pharmaceutical composition comprising the compound and use of the compound and pharmaceutical composition thereof in treating influenza. The present invention provides a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, The compound of the present invention can inhibit influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties.

  这项发明属于医学领域，特别涉及一种作为流感病毒复制抑制剂的新型化合物及其制备方法，包括该化合物的药物组合物和在治疗流感中使用该化合物和药物组合物。本发明提供具有化学式（I）或其立体异构体、互变异构体、N-氧化物、溶剂合物、代谢物、药学上可接受的盐或其前药的化合物。本发明的化合物可以很好地抑制流感病毒，并/或具有较低的细胞毒性，在体内药代动力学性能和体内药效学性能更好。
• Imidazole lipoxygenase inhibitors
  申请人：Pfizer Inc.

  公开号：US05753682A1

  公开（公告）日：1998-05-19

  Certain novel imidazole derivatives having the ability to inhibit the lipoxygenase enzyme and having formula (I), wherein Y is hydrogen, C.sub.1 -C.sub.8 alkyl, halosubstituted C.sub.1 -C.sub.4 alkyl, phenyl, substituted phenyl, C.sub.7 -C.sub.14 phenylalkyl, C.sub.7 -C.sub.14 (substituted phenyl)alkyl, pyridyl, substituted pyridyl, C.sub.6 -C.sub.13 pyridylalkyl or C.sub.6 -C.sub.13 (substituted pyridyl)alkyl, wherein each substituent is independently halo, nitro, cyano, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halosubstituted C.sub.1 -C.sub.4 alkyl, halosubstituted C.sub.1 -C.sub.4 alkoxy, NR.sup.4 R.sup.5, CO.sub.2 R.sup.4 or CONR.sup.4 R.sup.5, wherein R.sup.4 and R.sup.5 are each, independently, hydrogen or C.sub.1 -C.sub.6 alkyl; Ar.sup.1 and Ar.sup.2 are each, independently, phenylene, mono-substituted phenylene or di-substituted phenylene, wherein the substituents are, independently, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo-substituted C.sub.1 -C.sub.4 alkyl or halo-substituted C.sub.1 -C.sub.4 alkoxy; X and X.sup.1 are each, independently, O, S, SO or SO.sub.2 ; R' is hydrogen or C.sub.1 -C.sub.4 alkyl; and R.sup.2 and R.sup.3 are each, independently, methylene, ethylene or propylene. These compounds are useful for the treatment of disease states such as bronchial asthma, skin disorders and arthritis in mammals, and as the active ingredient in pharmaceutical compositions for treating such conditions.

  具有抑制脂氧酶酶活性能力的某些新型咪唑衍生物具有以下结构式（I），其中Y为氢、C.sub.1 -C.sub.8烷基、卤代C.sub.1 -C.sub.4烷基、苯基、取代苯基、C.sub.7 -C.sub.14苯基烷基、C.sub.7 -C.sub.14（取代苯基）烷基、吡啶基、取代吡啶基、C.sub.6 -C.sub.13吡啶基烷基或C.sub.6 -C.sub.13（取代吡啶基）烷基，其中每个取代基独立地为卤素、硝基、氰基、C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基、卤代C.sub.1 -C.sub.4烷基、卤代C.sub.1 -C.sub.4烷氧基、NR^4R^5、CO_2R^4或CONR^4R^5，其中R^4和R^5各自独立地为氢或C.sub.1 -C.sub.6烷基；Ar^1和Ar^2各自独立地为苯基、单取代苯基或双取代苯基，其中取代基各自独立地为卤素、C.sub.1 -C.sub.4烷基、C.sub.1 -C.sub.4烷氧基、卤代C.sub.1 -C.sub.4烷基或卤代C.sub.1 -C.sub.4烷氧基；X和X^1各自独立地为O、S、SO或SO_2；R'为氢或C.sub.1 -C.sub.4烷基；R^2和R^3各自独立地为亚甲基、乙烯基或丙烯基。这些化合物可用于治疗哺乳动物的疾病状态，如支气管哮喘、皮肤疾病和关节炎，并作为治疗这些疾病条件的药物组合物中的活性成分。
• Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitors
  作者：Manman Wei、Xia Peng、Li Xing、Yang Dai、Ruimin Huang、Meiyu Geng、Ao Zhang、Jing Ai、Zilan Song

  DOI：10.1016/j.ejmech.2018.05.005

  日期：2018.6

  Starting from the phase II clinical FGFR inhibitor lucitanib (2), we conducted a medicinal chemistry approach by opening the central quinoline skeleton coupled with a scaffold hopping process thus leading to a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives. Compound 25a was identified to show selective and equally high potency against FGFR1/2 and VEGFR2 with IC50

  从II期临床FGFR抑制剂lucitanib（2）开始，我们通过打开中心喹啉骨架和脚手架跳跃过程进行了药物化学研究，从而开发出一系列新颖的2-benzamide-4-（6-oxy-N -甲基-1-萘酰胺）-吡啶衍生物。鉴定出化合物25a显示出对FGFR1 / 2和VEGFR2的选择性且同样高的效力，IC 50值小于5.0 nM。观察到对FGFR1 / 2和VEGFR2异常癌细胞均具有显着的抗增殖作用。在SNU-16异种移植模型中，化合物25a在10 mg / kg和50 mg / kg的剂量下分别显示25.0％和81.0％的肿瘤生长抑制率，体重减轻了5％和10％。鉴于在临床前研究中发现FGF和VEGF在肿瘤血管生成中具有协同增效作用，